Fred Eshelman Distinguished Professor and Chair
University of North Carolina at Chapel Hill
2011 - present Chair, Chemical Biology & Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
2007 - present Fred Eshelman Distinguished Professor, University of North Carolina; Chemistry, College of Arts & Sciences, Chemical Biology & Medicinal Chemistry, Eshelman School of Pharmacy, Pharmacology, School of Medicine, and the Lineberger Comprehensive Cancer Center
1996 - 20017 Professor of Biochemistry, Albert Einstein College of Medicine of Yeshiva University and Member, Albert Einstein Comprehensive Cancer Center
1985 - 1995 Assistant, Associate, and Full Professor of Chemistry, State University of New York at Buffalo
Postdoctoral Fellow, The Rockefeller University with E. Thomas Kaiser
Ph.D., Chemistry, The University of California at Los Angeles, with Robert. V. Stevens
B.S., Biological Sciences, The University of California at Irvine
Co-Chair, The 23rd American Peptide Symposium and 6th International Peptide Symposium in Hawaii, 2013
du Vigneaud Award Committee
Scientific Advisory Committee on Cancer Drug Development, American Cancer Society, 1996 - 97; Chemical and Related Sciences Special Emphasis Study Section, National Institutes of Health, 1994; Clinical and Experimental Therapeutics Study Section, The USAMRMC Breast Cancer Research Program, 1997; Chemical and Related Sciences Special Emphasis Study Section, NIH, 1997; International Advisory Board, The International Conference on Inhibitors of Protein Kinases, Warsaw, Poland, 1998; Organizer of the symposium on "Biosensors: Visualizing the Chemistry of Living Cells", American Chemical Society Western Regional Meeting, 1999; Biochemistry Study Section, NIH, 1999; Bio-Organic and Natural Products Chemistry Study Section, NIH, 2000 - 04; Scientific Advisory Board, Keryx Biopharmaceuticals, 2000-2002, International Advisory Board, The 2nd International Conference on Inhibitors of Protein Kinases, Warsaw, Poland, 2001; Guest Editor, Accounts of Chemical Research Special Issue on Signal Transduction, 2003; International Advisory Board, The 3rd International Conference on Inhibitors of Protein Kinases, Warsaw, Poland, 2003; Scientific Advisory Board, Panomics, 2003 - 2008; Editorial Advisory Board, Current Organic Synthesis, 2003 - 2008; Editorial Advisory Board, Accounts Chemical Research, 2004-; Scientific Co-founder, OnSetThera Pharmaceuticals, 2004; Member, The Harvey Society, 2005 - 2007; Member, American Society for Cell Biology, 2006 - 2008; Consultant, Sigma - Aldrich, 2006 - 2007; International Advisory Board, The 6th International Conference on Inhibitors of Protein Kinases, Warsaw, Poland, 2009; Macromolecular Structure and Function E Study Section, National Institutes of Health, 2010 and 2012 - 16; External Reviewer, Department of Medicinal Chemistry, University of Utah, 2011; External Reviewer, Purdue University Cancer Center, 2011; International Advisory Board, The 7th International Conference on Inhibitors of Protein Kinases, Warsaw, Poland, 2012.
Awards & Honors
NIH Postdoctoral Fellow, Marion Merrell Dow Lecture, Merck/American Association for the Advancement of Science Lecture, Sam Rosen Award, Leo M. Davidoff Society, Olympia Dukakis/Richard Zorich Award, AAAS Fellow.
The Lawrence research program is multifaceted; encompassing the fields of organic and peptide synthesis, photochemistry, enzymology, cell and molecular biology, and microscopy. The research group's expertise lies in the design, synthesis, characterization, and application of light-responsive agents, including sensors, inhibitors, activators, proteins, gene-expression, and drug delivery systems. These agents have been used to probe, perturb, and reengineer biological systems.
I had the pleasure of serving as the co-Chair of the 23rd American Peptide Symposium and the 6th International Peptide Symposium in Hawaii, 2013). The meeting brought attendees from around the world representing a diversity of interests and viewpoints. Of course, this is the strength of our science, which serves as a bridge connecting the disciplines of chemistry, biology, engineering, and medicine. I believe that we must continue to embrace this strength, by encouraging collaborations with our partners in related scientific disciplines, promoting mutually beneficial interactions between the not-for-profit and for-profit sectors, and establishing effective and productive relationships with other national and international professional societies. At a time when financial support for science has stagnated and many question the validity, conclusions, and integrity of scientists, I strongly support the mission of the APS, which not only provides "a forum for advancing and promoting knowledge of the chemistry and biology of peptides", but also works hand-in-hand with biomedical societies throughout the world.
On Tuesday (March 9th) and Thursday (March 11th), APS FASEB representative Dr. Mark Distefano along with other FASEB representatives and staff met with congressional staff members from both the House of Representatives and Senate to encourage them to increase the budgets for both NIH and NSF.
Updated 3/30/21 Read about recent things happening at FASEB, a coalition of scientific societies including APS, that represents over 130,000 biological and biomedical researchers from around the world.